MIRA
MIRA Pharmaceuticals, Inc.·Healthcare
1.00
2.304%(−0.02)
Market ClosedLast Updated: — ET
52W L: $0.8352W H: $2.45
MIRA NEWS
accessnewswire.com
Mar 23
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain MIAMI, FL / ACCESS Newswire / March 23, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical data demonstrating that Mira-55 did not produce cannabinoid-like central nervous system (CNS) side effects across a comprehensive battery of validated behavioral assays. The observed profile was differentiated from both Δ9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, and the CB1 receptor antagonist rimonabant.
newsfilecorp.com
Mar 18
Visionstate Reports Accelerating Subscription Growth and Expansion of MIRA Compliance Platform
Edmonton, Alberta--(Newsfile Corp. - March 18, 2026) - Visionstate Corp. (TSXV: VIS) today provided an operational update highlighting continued subscription growth and expanding adoption of its MIRA compliance platform, building on the baseline metrics previously reported for fiscal 2026. Since the Company's last update, Visionstate has added 11 new location subscriptions across 12 installations during the period from early February through mid-March 2026, further strengthening its recurring revenue base.
accessnewswire.com
Mar 4
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2
Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS Newswire / March 4, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neuropathic and inflammation-driven pain conditions, metabolic disorders, and oncology-related indications, today announced completion of dosing in its Phase 1 clinical trial evaluating Ketamir-2, the Company's proprietary selective oral NMDA receptor modulator. The randomized, double-blind, placebo-controlled study enrolled 56 healthy adult volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.
defenseworld.net
Mar 3
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA - Get Free Report) saw a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 568,283 shares, an increase of 29.4% from the January 29th total of 439,335 shares. Based on an average daily volume of 136,480 shares, the short-interest ratio
newsfilecorp.com
Feb 19
Visionstate Repositions Under MIRA Compliance Platform and Reports Subscription Growth
Edmonton, Alberta--(Newsfile Corp. - February 19, 2026) - Visionstate Corp. (TSXV: VIS) today announced a strategic repositioning of its technology offerings under a unified compliance-focused platform brand, MIRA, and provided an update on subscription activity entering fiscal 2026. "For several years, Visionstate has been described primarily as an IoT (Internet of Things) facility management solution," said John Putters, CEO of Visionstate Corp. "As regulatory and operational accountability requirements increase, we believe it is more accurate to describe our business as a compliance-focused subscription platform.
accessnewswire.com
Feb 3
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual Meeting MIAMI, FLORIDA / ACCESS Newswire / February 3, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neuropathic and inflammation-driven pain conditions, metabolic disorders, and oncology-related indications, today announced that it has initiated dosing in the final cohort of its Phase 1 multiple ascending dose (MAD) clinical trial evaluating Ketamir-2, its lead oral NMDA receptor antagonist. To date, 50 healthy volunteers have already been dosed, while dosing in the final cohort is underway, with 6 last subjects remaining.
